ALEXION PHARMACEUTICALS, INC.: insider trades · United States · SEC (Form 4)

About ALEXION PHARMACEUTICALS, INC.

Alexion Pharmaceuticals, Inc. is a U.S. biopharmaceutical company historically focused on rare and ultra-rare diseases. It was founded in 1992 at Science Park in New Haven, Connecticut, and built its business model around a clear specialty-pharma thesis: target severe conditions with high unmet medical need and develop premium therapies with strong clinical differentiation. The company is associated operationally with Boston, Massachusetts, while retaining deep historical roots in Connecticut. Alexion was acquired by AstraZeneca in 2021, but the Alexion name still appears in regulatory filings and corporate references, including SEC Form 4 insider-transaction documentation and legacy reporting entities. The company was previously listed in the United States on NASDAQ, and it remains best understood as a U.S. rare-disease biotech rather than a broad diversified pharmaceutical company. From an operating perspective, Alexion established itself through a franchise built on orphan-drug commercialization. Its flagship products have included Soliris (eculizumab) and Ultomiris (ravulizumab), therapies used in diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The portfolio has also included Strensiq (asfotase alfa) for hypophosphatasia, Kanuma (sebelipase alfa) for lysosomal acid lipase deficiency, and Andexxa (andexanet alfa) for reversal of factor Xa inhibitors in life-threatening bleeding. This product mix gave Alexion a defensible competitive position: very small patient populations, limited direct competition, high clinical and regulatory expertise requirements, and pricing power supported by the severity of the underlying diseases and the lack of meaningful therapeutic alternatives. Geographically, Alexion has operated with a global footprint, but its core commercial and regulatory base has been the United States, complemented by international sales in developed markets. For investors in France, Belgium, and Switzerland, the key analytical point is that Alexion’s economics have historically been driven less by broad volume growth than by specialty franchise execution, medical affairs strength, and access to specialist treatment centers. The company is not a traditional mass-market pharma player; it is a rare-disease platform with concentrated assets and a highly targeted customer base. A major recent milestone was the completion of the AstraZeneca transaction, which turned Alexion from an independent rare-disease champion into a strategic component of a larger global pharmaceutical group. That corporate event is the defining development in the company’s modern history. For market participants following SEC Form 4 insider transactions, Alexion remains relevant because U.S. regulatory filings continue to reference the legacy issuer/entity structure. In summary, Alexion’s investment profile is best framed as a specialty rare-disease franchise with strong historical brands, global reach, and a post-acquisition profile anchored within AstraZeneca.